Navigation Links
Everist Genomics Laboratory Receives Approval From U.S. Regulatory Authorities For High Complexity Clinical Testing
Date:3/7/2011

ANN ARBOR, Mich. March 7, 2011 /PRNewswire/ -- Everist Genomics announced today that it has received U.S. Clinical Laboratory Improvement Amendment (CLIA) certification required for the company to launch its OncoDefender-CRC assay, a prognostic test for assessing the risk of cancer recurrence for patients with early stage colorectal cancer.  Because OncoDefender-CRC is categorized by CLIA as a high complexity test, it is evaluated against the most stringent federally-mandated requirements, ensuring that the company's testing laboratory meets quality standards for accuracy, reliability and timeliness of patient results.

(Logo: http://photos.prnewswire.com/prnh/20110110/NY26865LOGO)

"Obtaining this regulatory certification represents a significant milestone in the company's commercial development path," said Prasad Sunkara, President and CEO of Everist Genomics. "Although Everist Genomics has always operated under rigorous scientific standards, it is encouraging to receive this type of regulatory validation from an independent authority. We expect that meeting the challenging certification guidelines enabling our clinical laboratory to perform high-complexity testing will give physicians and patients greater confidence when ordering the OncoDefender-CRC test."

OncoDefender-CRC, which measures the expression of colorectal cancer-specific genes, is the first and only molecular prognostic test capable of accurately predicting the risk of recurrence in patients previously treated with surgical resection of a Stage I/II colon cancer tumor or Stage I rectal cancer tumor. The company will officially launch the test later this month.

Everist Genomics released data from its external validation study of OncoDefender-CRC at the American Society of Clinical Oncology's 2011 Gastrointestinal Cancers Symposium in January. The study, which was conducted by Mayo Validation Support Services, indicated that the performance characteristics of the Onc
'/>"/>

SOURCE Everist Genomics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Everist Genomics Announces External Validation of OncoDefender™-CRC Test for Predicting Recurrence Risk for Stage I and II Colorectal Cancer Patients
2. Rosetta Genomics Announces Conference Call and Webcast of Second Quarter Financial Results
3. DOE JGI Director Eddy Rubin highlights the genomics of plant-based biofuels in the journal Nature
4. Rosetta Genomics Reports Second Quarter 2008 Financial Results
5. Rosetta Genomics and the National Institute of Health (NIH) to Identify Potential MicroRNA Drug Targets for HIV
6. eGenomics Awarded First U.S. Patent Covering Rapid DNA Sequencing Technology Platform to Control Hospital-Acquired Infections
7. Transgenomic Announces Partnership With Key Genomics for Ovarian Cancer Assay to Guide Therapeutic Options
8. U.S. Genomics Inc. Receives $4.5 Million Investment from BD
9. Helix BioPharma to Present L-DOS47 Research Findings at the National Research Council of Canadas Eighth Annual General Meeting of the Genomics and Health Initiative in Saskatoon, Canada
10. TIBCO Spotfire and INTEGROMICS Announce Genomics Data Analysis Solution to Radically Speed Drug Research and Development
11. LI-COR Biosciences Offers $1.75 Million in Matching Funds for Undergraduate Genomics Education
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , CA (PRWEB) , ... July 30, 2015 ... ... the successful completion of a field clinical study of its canine osteoarthritis stem ... together with Aratana Therapeutics (Kansas City, KS) and will be marketed in the ...
(Date:7/30/2015)... July 30, 2015 Ascendis Pharma A/S ... applies its innovative TransCon technology to address significant ... from a six-month Phase 2 study to evaluate ... Hormone in 53 treatment-naïve, pre-pubertal children with growth ... extremely pleased with the top-line results from our ...
(Date:7/30/2015)... ... 30, 2015 , ... GEA's Pony™ NS2006L is ... up to 1500 bar. The sanitary design gauge of the NS2006L is well ... The Pony™ NS2006L homogenizer is an ideal solution for the processing of ...
(Date:7/29/2015)... US-Australian drug discovery company, Novogen Limited (ASX: NRT; NASDAQ: ... progressing its ground-breaking technology platforms to Phase 1 clinical ... Company delivers the best value for shareholders. ... the Company currently had an extensive program of activities ... academic partnerships and initiatives, and he was working with ...
Breaking Biology Technology:VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10
... Keryx Biopharmaceuticals,Inc. (Nasdaq: KERX ) today announced ... present an overview of the Company,s cancer,pipeline at ... Conference,in San Francisco. Dr. Henderson,s presentation will take ... Dr. Henderson,s presentation will be webcast live ...
... 17 BioMed Realty Trust, Inc.,(NYSE: BMR ) ... a,third quarter 2007 dividend of $0.31 per share of ... of $1.24 per common share. BioMed also announced ... $0.46094 per share of the company,s 7.375% Series A ...
... Surgery at the Forefront, SACRAMENTO, Calif., Sept. ... has formed a new company, Curexo Medical, Inc.,(CMI), ... Surgical Services,Inc. (ISS). Under the licensing agreement, Curexo, ... to CMI. Curexo Medical, Inc., located in ...
Cached Biology Technology:Keryx Biopharmaceuticals to Present at Bank of America Investment Conference 2BioMed Realty Trust Declares Third Quarter 2007 Common Stock and Preferred Stock Dividends 2New Orthopedic Surgical Robotics Company Opens Its Doors; Files with the FDA for Clearance of Its Flagship Product 2
(Date:7/21/2015)... YORK , July 21, 2015 ... systems, as seen in the recent U.S. Office ... a solution to the infosec conundrum, but developers ... is stored. To address this dilemma, Biometrics-as-a-Service provider ... its Biometric Tokenization SDK for third party integration. ...
(Date:7/13/2015)... SAN JOSE, Calif. , July 13, 2015 ... the leading developer of human interface solutions, today ... second generation touch and display driver integration (TDDI) ... solution is the first to combine Synaptics , ... expertise with proven display driver technology developed in ...
(Date:7/9/2015)... SAN JOSE, Calif. , July 9, 2015 /PRNewswire/ ... human interface solutions, announced today that it will report ... 2015 on Thursday, July 30, 2015 after the close ... call for analysts and investors at 2:00 p.m. PT ... information.    To participate on the live ...
Breaking Biology News(10 mins):HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2
... This news release is available in French ... 2013 From office towers to shopping malls, educational institutions to ... all electricity consumed in Canada. Thanks to new research funding for ... and source of pollution. More than $2 million in funding ...
... in Florence last week. It provided us with some of the ... Did life begin on Mars rather than on earth?, Chelyabinsk meteor ... Bird", was probably a herbivore Goldschmidt2014 is due to ... so if you want to attend, put the dates in your ...
... planarian flatworms have the remarkable ability to regrow any missing ... study the molecular basis of regeneration. Over ... that differ depending on the severity of the injury they ... puncture wound reacts at the cellular and molecular levels quite ...
Cached Biology News:Buildings of the future 2Tissue loss triggers regeneration in planarian flatworms 2